Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of two 50-mg vildagliptin tablet formulations in healthy Thai subjects under fasting conditions
TCTR20220613003Phase 1Unknown
- Sponsor
- T.O. Chemicals
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by T.O. Chemicals. Primary endpoints: AUC0-t of vildagliptin, AUC0-inf of vildagliptin and 3 more. Status: unknown.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20220613003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220613003.